UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 322

Sortiert nach

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

Nature medicine, 2020-01, Vol.26 (1), p.47-51

2020

Link zum Volltext

Verfügbarkeit prüfen

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2016-10, Vol.34 (28), p.3383-3389

2016

Link zum Volltext

Verfügbarkeit prüfen

Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety

Therapeutic Advances in Respiratory Disease, 2018-01, Vol.12, p.1753466618801167-1753466618801167

Hida, Toyoaki

2018

Link zum Volltext

Verfügbarkeit prüfen

Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)

Clinical cancer research, 2019-09, Vol.25 (18), p.5485-5492

2019

Link zum Volltext

Verfügbarkeit prüfen

LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both

Journal of clinical oncology, 2013-09, Vol.31 (27), p.3335-3341

2013

Link zum Volltext

Verfügbarkeit prüfen

Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study

European journal of cancer (1990), 2019-05, Vol.113, p.78-86

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non‐small cell lung cancer

Cancer science, 2020-12, Vol.111 (12), p.4442-4452

2020

Link zum Volltext

Verfügbarkeit prüfen

CH5424802 (RO5424802) for patients with ALK -rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

The lancet oncology, 2013-06, Vol.14 (7), p.590-598

2013

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement

International journal of molecular sciences, 2020-04, Vol.21 (7), p.2623

2020

Link zum Volltext

Verfügbarkeit prüfen

Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis

Cancer letters, 2017-01, Vol.385, p.215-224

2017

Link zum Volltext

Verfügbarkeit prüfen

Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer

Oncotarget, 2017-11, Vol.8 (61), p.103117-103128

2017

Link zum Volltext

Verfügbarkeit prüfen

Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non‐small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX‐Lung 3

Cancer science, 2015-09, Vol.106 (9), p.1202-1211

2015

Link zum Volltext

Verfügbarkeit prüfen

Diagnosis by Volatile Organic Compounds in Exhaled Breath from Lung Cancer Patients Using Support Vector Machine Algorithm

Sensors (Basel, Switzerland), 2017-02, Vol.17 (2), p.287-287

2017

Link zum Volltext

Verfügbarkeit prüfen

Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer

Lung cancer (Amsterdam, Netherlands), 2020-01, Vol.139, p.195-199

2020

Link zum Volltext

Verfügbarkeit prüfen

Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib

Clinical cancer research, 2006-10, Vol.12 (19), p.5764-5769

2006

Link zum Volltext

Verfügbarkeit prüfen

Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis

BMC cancer, 2021-08, Vol.21 (1), p.1-924, Article 924

2021

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA3 trial

Cancer science, 2018-06, Vol.109 (6), p.1930-1938

2018

Link zum Volltext

Verfügbarkeit prüfen

Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence

Journal of clinical oncology, 2005-04, Vol.23 (11), p.2513-2520

2005

Link zum Volltext

Verfügbarkeit prüfen

Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND‐9

Cancer science, 2018-09, Vol.109 (9), p.2863-2872

2018

Link zum Volltext

Verfügbarkeit prüfen

Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study

Cancer science, 2021-04, Vol.112 (4), p.1556-1566

2021

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 322

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(256)
Mit Volltextzugriff
(315)

Publikationsform

Artikel
(315)
Berichte
(7)

Sprache

Englisch
(285)
Japanisch
(76)

Erscheinungsjahr

n.n

Thema

Science & Technology
(183)
Life Sciences & Biomedicine
(180)
Oncology
(159)
Humans
(141)
Female
(104)
Male
(100)
Middle Aged
(95)
Aged
(91)
Lung Cancer
(89)
Lung Neoplasms - Drug Therapy
(80)
Adult
(77)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(64)
Lung Neoplasms - Genetics
(64)
Lung Neoplasms - Pathology
(63)
Mutation
(52)
Tumors
(50)
Respiratory System
(49)
Biological And Medical Sciences
(44)
Carcinoma, Non-Small-Cell Lung - Genetics
(42)
Medical Sciences
(42)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(43)
Journal Of Thoracic Oncology
(28)
Lung Cancer
(20)
Cancer Science
(17)
Japanese Journal Of Lung Cancer
(17)
Cancer Research
(14)
Japanese Journal Of Clinical Oncology
(12)
Haigan. Lung Cancer
(10)
Clinical Cancer Research
(9)
Annals Of Oncology
(8)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration

Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study

Differential Crizotinib Response Duration Among ALK Fusion Variants in ALK-Positive Non-Small-Cell Lung Cancer

Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety

Clinical Efficacy and Safety of Nivolumab: Results of a Multicenter, Open-label, Single-arm, Japanese Phase II study in Malignant Pleural Mesothelioma (MERIT)

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both

Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study

Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non‐small cell lung cancer

CH5424802 (RO5424802) for patients with ALK -rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study

Efficacy of Immune Checkpoint Inhibitor Monotherapy for Advanced Non-Small-Cell Lung Cancer with ALK Rearrangement

Statin suppresses Hippo pathway-inactivated malignant mesothelioma cells and blocks the YAP/CD44 growth stimulatory axis

Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer

Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non‐small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX‐Lung 3

Diagnosis by Volatile Organic Compounds in Exhaled Breath from Lung Cancer Patients Using Support Vector Machine Algorithm

Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer

Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum‐pemetrexed for T790M mutation‐positive advanced non–small cell lung cancer

Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib

Pre-existing interstitial lung disease is associated with onset of nivolumab-induced pneumonitis in patients with solid tumors: a retrospective analysis

Osimertinib in Japanese patients with EGFR T790M mutation‐positive advanced non‐small‐cell lung cancer: AURA3 trial

Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence

Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND‐9

Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study

Suchergebnisse filtern